Literature DB >> 21180555

Improving compliance with helicobacter pylori eradication therapy: when and how?

John P Anthony O'Connor1, Ikue Taneike, Colm O'Morain.   

Abstract

Compliance with therapy is the single most important factor in Helicobacter pylori (H. pylori) eradication. Poorer levels of compliance with therapy are associated with significantly lower levels of eradication. Numerous factors can contribute to achieving good levels of compliance. These include the complexity and duration of treatment. It is also important that the physician is motivated to ensure eradication is confirmed and the patient is sufficiently informed to empower him or her to achieve high levels of compliance. Compliance is also contingent on medication regimes that are simple, safe, tolerable and efficacious. The opportunity to improve compliance exists at every point of contact between the patient and the medical services. Experts and opinion leaders in the field can play a role by ensuring that physicians are educated and motivated enough to encourage and support compliance with H. pylori eradication therapy. Both patients and physicians need to be aware of the importance of the bacterium in causing disease. The importance of the doctor-patient relationship is paramount. Pragmatic strategies that may be of assistance may come in the form of polypills, combined Blister Packs, adjuvant therapies and modified release compounds. Colleagues such as pharmacists and nurse specialists can also play an important role and should be actively engaged. Structured aftercare and follow up offers the best chance for ensuring compliance and subsequent eradication of the H. pylori pathogen.

Entities:  

Keywords:  Helicobacter pylori; compliance; gastric cancer

Year:  2009        PMID: 21180555      PMCID: PMC3002536          DOI: 10.1177/1756283X09337342

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  37 in total

1.  A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection.

Authors:  X Calvet; N García; T López; J P Gisbert; E Gené; M Roque
Journal:  Aliment Pharmacol Ther       Date:  2000-05       Impact factor: 8.171

2.  Fluoroquinolones and risk of Achilles tendon disorders: case-control study.

Authors:  P D van der Linden; M C J M Sturkenboom; R M C Herings; H G M Leufkens; B H Ch Stricker
Journal:  BMJ       Date:  2002-06-01

3.  Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients.

Authors:  D J Kearney; A Brousal
Journal:  Dig Dis Sci       Date:  2000-02       Impact factor: 3.199

4.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

5.  Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study.

Authors:  Rocco Maurizio Zagari; Gabriele Bianchi-Porro; Roberto Fiocca; Giovanni Gasbarrini; Enrico Roda; Franco Bazzoli
Journal:  Gut       Date:  2006-10-06       Impact factor: 23.059

6.  New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study.

Authors:  L G V Coelho; L D Moretzsohn; W L S Vieira; M A Gallo; M C F Passos; J M Cindr; M C Cerqueira; L Vitiello; M L Ribeiro; S Mendonça; J Pedrazzoli-Júnior; L P Castro
Journal:  Aliment Pharmacol Ther       Date:  2005-03-15       Impact factor: 8.171

7.  Enhancing compliance not a prerequisite for effective eradication of Helicobacter pylori: the HelP Study.

Authors:  A Henry; R G Batey
Journal:  Am J Gastroenterol       Date:  1999-03       Impact factor: 10.864

8.  The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication.

Authors:  Mi Na Kim; Nayoung Kim; Sang Hyup Lee; Young Soo Park; Jin-Hyeok Hwang; Jin-Wook Kim; Sook-Hyang Jeong; Dong Ho Lee; Joo Sung Kim; Hyun Chae Jung; In Sung Song
Journal:  Helicobacter       Date:  2008-08       Impact factor: 5.753

9.  Survey of the opinions, knowledge and practices of surgeons and internists regarding Helicobacter pylori test-and-treat policy.

Authors:  Yaron Niv; Galia Abuksis
Journal:  J Clin Gastroenterol       Date:  2003-02       Impact factor: 3.062

10.  Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy.

Authors:  Michael Dickson; Craig A Plauschinat
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

View more
  11 in total

1.  Pyridodiazepine amines are selective therapeutic agents for helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacy.

Authors:  Boudewijn L M de Jonge; Amy Kutschke; Joseph V Newman; Michael T Rooney; Wei Yang; Christer Cederberg
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Loose ends in the eradication of Helicobacter pylori infection.

Authors:  Armando Peixoto; Marco Silva; Rui Gaspar; Rui Morais; Rosa Ramalho; Guilherme Macedo; João Santos-Antunes
Journal:  J Transl Int Med       Date:  2016-12-30

Review 3.  Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance.

Authors:  Sinéad M Smith; Colm O'Morain; Deirdre McNamara
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 4.  Potent Acid Suppression with PPIs and P-CABs: What's New?

Authors:  Richard H Hunt; Carmelo Scarpignato
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

5.  Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China.

Authors:  Chun-Hua Wang; Sheng-Tao Liao; Jun Yang; Chun-Xia Li; Ying-Ying Yang; Ran Han; Dong-Feng Chen; Chun-Hui Lan
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

6.  Probiotics improve the efficacy of standard triple therapy in the eradication of Helicobacter pylori: a meta-analysis.

Authors:  Christine S M Lau; Amanda Ward; Ronald S Chamberlain
Journal:  Infect Drug Resist       Date:  2016-12-07       Impact factor: 4.003

7.  Clinical background factors affecting outcomes of Helicobacter pylori eradication therapy in primary care.

Authors:  Nozomi Yokota; Ryusuke Ae; Masaki Amenomori; Koji Kitagawa; Takuya Nakamura; Tetsuro Yokota; Kato Masato; Teppei Sasahara; Yuri Matsubara; Koki Kosami; Yoshikazu Nakamura
Journal:  J Gen Fam Med       Date:  2019-04-10

8.  Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial.

Authors:  So Jeong Kim; Jun-Won Chung; Hyun Sun Woo; Su Young Kim; Jung Ho Kim; Yoon Jae Kim; Kyoung Oh Kim; Kwang An Kwon; Dong Kyun Park
Journal:  World J Gastroenterol       Date:  2019-12-14       Impact factor: 5.742

9.  A comparative study of the effect of 10-day esomeprazole containing levofloxacin versus clarithromycin sequential regimens on the treatment of Iranian patients with Helicobacter pylori infection.

Authors:  Marjan Mokhtare; Mehdi Nikkhah; Behdad Behnam; Shahram Agah; Mansour Bahardoust; Mohsen Masoodi; Amirhosein Faghihi
Journal:  Indian J Pharmacol       Date:  2020 Jul-Aug       Impact factor: 1.200

10.  Helicobacter pylori Eradication Therapy: Current Availabilities.

Authors:  M Gasparetto; M Pescarin; G Guariso
Journal:  ISRN Gastroenterol       Date:  2012-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.